New Drug Approvals
JULY 18, 2025
It acts as an RNA-dependent RNA polymerase (RdRp) inhibitor, the same mechanism as the previously approved molnupiravir and remdesivir. It acts as an RNA-dependent RNA polymerase (RdRp) inhibitor, the same mechanism as the previously approved molnupiravir and remdesivir. April 2011). 81 (7): 848–855. doi : 10.1016/j.bcp.2011.01.001.
Drug Target Review
JUNE 6, 2023
Delivery of therapy is being evaluated through injections of DNA and RNA encoding IL-12, viral vectors, and other exploratory platforms designed to bring IL-12 in close proximity to the tumour and avoid excessive IL-12 in systemic circulation. Some approaches have already reached the clinical trial stage, with others not far behind.
Expert insights. Personalized for you.
Let's personalize your content